To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity

Hemophilia A is a bleeding disorder characterized by the absence or dysfunction of blood coagulation factor VIII (FVIII). Patients are treated with regular infusions of FVIII concentrate. In response to treatment, approximately 30% of patients with severe hemophilia A develop inhibitory antibodies targeting FVIII. Both patient and treatment related risk factors for inhibitor development have been described. Multiple studies comparing the immunogenicity of recombinant and plasma-derived FVIII have yielded conflicting results.

http://www.bloodreviews.com/article/S0268-960X(17)30044-9/fulltext?rss=yes

Source: Blood Reviews - July 4, 2017 Category: Hematology Authors: Robin Hartholt, Alice S. van Velzen, Ivan Peyron, Anja ten Brinke, Karin FijnvanDraat, Jan Voorberg Tags: Review Source Type: research